<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00098397</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02641</org_study_id>
    <secondary_id>MDA-2003-0895</secondary_id>
    <secondary_id>N01CM17003</secondary_id>
    <secondary_id>CDR0000404163</secondary_id>
    <nct_id>NCT00098397</nct_id>
  </id_info>
  <brief_title>FR901228 in Treating Patients With Metastatic Breast Cancer</brief_title>
  <official_title>A Phase II Study Of Single Agent Depsipeptide (FK228) In Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase II trial is studying how well FR901228 works in treating patients with metastatic&#xD;
      breast cancer. Drugs used in chemotherapy, such as FR901228, work in different ways to stop&#xD;
      the growth of tumor cells, either by killing the cells or by stopping them from dividing.&#xD;
      FR901228 may also stop the growth of tumor cells by blocking some of the enzymes needed for&#xD;
      cell growth&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the efficacy and safety of FR901228 (depsipeptide) in patients with metastatic&#xD;
      breast cancer.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the clinical activity of this drug, in terms of progression-free survival, in&#xD;
      these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Courses repeat&#xD;
      every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 12-37 patients will be accrued for this study within 2.4-12.3&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2005</start_date>
  <primary_completion_date type="Actual">September 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy (complete and partial response) according to RECIST</measure>
    <time_frame>Up to 14 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>From the first day of treatment to the first observation of disease progression or death due to any cause, assessed up to 14 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity as measured by the standard WHO grading system</measure>
    <time_frame>Up to 14 months after completion of study treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Male Breast Cancer</condition>
  <condition>Recurrent Breast Cancer</condition>
  <condition>Stage IV Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (romidepsin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>romidepsin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (romidepsin)</arm_group_label>
    <other_name>FK228</other_name>
    <other_name>FR901228</other_name>
    <other_name>Istodax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Optional correlative studies</description>
    <arm_group_label>Treatment (romidepsin)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed breast cancer&#xD;
&#xD;
               -  Metastatic disease&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
               -  At least 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques&#xD;
                  OR ≥ 10 mm by spiral CT scan&#xD;
&#xD;
               -  The following are not considered measurable disease:&#xD;
&#xD;
                    -  Bone disease only&#xD;
&#xD;
                    -  Pleural effusion&#xD;
&#xD;
                    -  Peritoneal effusion&#xD;
&#xD;
          -  Must have received prior anthracycline (doxorubicin or epirubicin) and/or taxane&#xD;
             (paclitaxel or docetaxel) as adjuvant therapy or for advanced disease&#xD;
&#xD;
               -  Therapy with high-dose regimens or bone marrow transplantation is considered 1&#xD;
                  prior regimen&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
          -  Performance status - ECOG 0-1&#xD;
&#xD;
          -  Performance status - Karnofsky 70-100%&#xD;
&#xD;
          -  More than 12 weeks&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  WBC ≥ 3,000/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  AST or ALT ≤ 2.5 times upper limit of normal&#xD;
&#xD;
          -  Creatinine normal&#xD;
&#xD;
          -  Creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
          -  QTc &lt; 500 msec&#xD;
&#xD;
          -  No New York Heart Association class III or IV congestive heart failure&#xD;
&#xD;
          -  No myocardial infarction within the past year&#xD;
&#xD;
          -  No uncontrolled dysrhythmia&#xD;
&#xD;
          -  No poorly controlled angina&#xD;
&#xD;
          -  No other significant cardiac disease&#xD;
&#xD;
          -  No history of serious ventricular arrhythmia (ventricular tachycardia or ventricular&#xD;
             fibrillation ≥ 3 beats in a row)&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No history of allergic reaction attributed to compounds of similar chemical or&#xD;
             biologic composition to FR901228&#xD;
&#xD;
          -  No active or ongoing infection&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  No other uncontrolled illness&#xD;
&#xD;
          -  No concurrent biologic agents&#xD;
&#xD;
          -  No more than 1 prior chemotherapy regimen for metastatic disease&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and&#xD;
             recovered&#xD;
&#xD;
          -  No prior FR901228 (depsipeptide)&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
          -  Prior hormonal therapy for metastatic disease or as adjuvant therapy allowed&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
          -  More than 2 weeks since prior minor surgery and recovered&#xD;
&#xD;
          -  More than 4 weeks since prior major surgery and recovered&#xD;
&#xD;
          -  Concurrent bisphosphonates allowed provided therapy was initiated ≥ 3 months ago&#xD;
&#xD;
          -  No concurrent agents that cause QTc prolongation&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
&#xD;
          -  No concurrent drugs known to have histone deacetylase activity (e.g., valproic acid)&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Massimo Cristofanilli</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>December 7, 2004</study_first_submitted>
  <study_first_submitted_qc>December 7, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2004</study_first_posted>
  <last_update_submitted>January 23, 2013</last_update_submitted>
  <last_update_submitted_qc>January 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Breast Neoplasms, Male</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Romidepsin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

